| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
94,670,000 |
| Market
Cap: |
90.88(M) |
| Last
Volume: |
940,193 |
Avg
Vol: |
714,677 |
| 52
Week Range: |
$0.754 - $7.66 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Assertio Therapeutics is a pharmaceutical company. Co.'s primary marketed products include: INDOCIN® (indomethacin) Suppositories and INDOCIN® (indomethacin) Oral Suspension, which is a suppository form and oral solution of indomethacin, a nonsteroidal anti-inflammatory drug (NSAID), approved for moderate to severe rheumatoid arthritis, ankylosing spondylitis and osteoarthritis; CAMBIA® (diclofenac potassium for oral solution), which is a prescription NSAID indicated for the acute treatment of migraine attacks in adults; and Otrexup® (methotrexate) injection, used to treat adults with severe, active rheumatoid arthritis, and children with active polyarticular juvenile idiopathic arthritis.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Stern Julian N |
Director |
– • – |
2008-11-25 |
4 |
B |
$1.37 |
$41,817 |
I/I |
29,070 |
133,333 |
2.1 |
- |
|
| Stern Julian N |
Director |
– • – |
2008-11-25 |
4 |
B |
$1.48 |
$32,623 |
I/I |
20,930 |
104,263 |
2.1 |
- |
|
| Tang Capital Management Llc |
10% Owner |
– – • |
2008-01-18 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
3,806,600 |
|
- |
|
| Zenoff David B |
Director |
– • – |
2007-11-06 |
4 |
B |
$2.59 |
$20,868 |
I/I |
8,000 |
10,845 |
2.1 |
- |
|
| Hamilton John F |
VP & CFO |
• – – |
2007-10-10 |
4 |
A |
$0.00 |
$0 |
D/D |
100,000 |
205,644 |
|
- |
|
| Hamilton John F |
VP & CFO |
• – – |
2007-06-12 |
4 |
OE |
$5.25 |
$131,250 |
D/D |
25,000 |
105,644 |
|
- |
|
| Shell John N |
VP, Operations |
• – – |
2007-05-31 |
4 |
S |
$4.35 |
$35,170 |
D/D |
(8,085) |
500,258 |
|
- |
|
| Fara John W |
President & CEO |
• • – |
2007-04-10 |
4 |
OE |
$3.00 |
$200,001 |
D/D |
66,667 |
171,677 |
|
- |
|
| Zenoff David B |
Director |
– • – |
2007-03-21 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
2,845 |
|
- |
|
| Shell John N |
VP, Operations |
• – – |
2007-01-16 |
4 |
OE |
$3.00 |
$24,999 |
D/D |
8,333 |
516,676 |
|
- |
|
| Hamilton John F |
VP & CFO |
• – – |
2006-12-21 |
4 |
OE |
$3.00 |
$90,000 |
D/D |
30,000 |
77,644 |
|
- |
|
| Fara John W |
President & CEO |
• • – |
2006-10-02 |
4 |
OE |
$0.90 |
$75,000 |
D/D |
83,333 |
105,000 |
|
- |
|
| Biovail Laboratories Inc |
10% Owner |
– – • |
2006-05-02 |
4 |
OE |
$2.16 |
$324,000 |
D/D |
150,000 |
4,242,032 |
|
- |
|
| Berner Bret |
VP, Product Development |
• – – |
2005-08-11 |
4 |
OE |
$5.20 |
$119,600 |
D/D |
23,000 |
627 |
|
- |
|
| Berner Bret |
VP, Product Development |
• – – |
2005-08-11 |
4 |
OE |
$1.71 |
$53,310 |
D/D |
23,000 |
23,627 |
|
- |
|
| Shell John N |
VP, Operations |
• – – |
2005-08-10 |
4 |
OE |
$0.09 |
$750 |
D/D |
8,333 |
508,343 |
|
- |
|
| Fara John W |
President & CEO |
• • – |
2004-08-11 |
4 |
B |
$4.10 |
$20,500 |
D/D |
5,000 |
21,677 |
2.81 |
- |
|
| Hamilton John F |
VP & CFO |
• – – |
2004-08-11 |
4 |
B |
$3.99 |
$39,900 |
D/D |
10,000 |
32,897 |
2.74 |
- |
|
| Shell John W |
Director |
– • – |
2004-03-08 |
4 |
GD |
$0.00 |
$0 |
D/D |
73,250 |
1,093,426 |
|
- |
|
| Callaghan Michael J |
Director |
– • – |
2004-03-08 |
4 |
S |
$6.99 |
$198,590 |
I/I |
(28,400) |
2,181,412 |
|
- |
|
| Callaghan Michael J |
Director |
– • – |
2004-03-05 |
4 |
S |
$6.90 |
$725,004 |
I/I |
(105,000) |
2,209,812 |
|
- |
|
246 Records found
|
|
Page 10 of 10 |
|
|
0.09 (8.57%) 
